ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model

Journal of Pathology

Volumn 227, Issue 3, 2012, Pages 298-305

  Busch, Stephanie E ^a,b   Gurley, Kay E ^a   Moser, Russell D ^a   Kemp, Christopher J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Endothelium; Ethyl carbamate; Haemorrhage; Liver; p14ARF; p19Arf; Tumour progression

Indexed keywords

ARF PROTEIN; CARCINOGEN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; URETHAN;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE REPRESSION; GENE TARGETING; LIVER HEMANGIOMA; LOSS OF FUNCTION MUTATION; MALE; MORBIDITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VASCULAR TUMOR;

ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HEMANGIOSARCOMA; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URETHANE;

EID: 84862023155     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4024     Document Type: Article

References (66)

1. Budd GT. Management of angiosarcoma. Curr Oncol Rep 2002; 4: 515-519.
2. Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol 2008; 97: 321-329. (Pubitemid 351358580)
3. Weihrauch M, Markwarth A, Lehnert G, et al . Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver. Hum Pathol 2002; 33: 884-892.
4. Hozo I, Miric D, Bojic L, et al . Liver angiosarcoma and hemangiopericytoma after occupational exposure to vinyl chloride monomer. Environ Health Perspect 2000; 108: 793-795.
5. Lee FI, Smith PM, Bennett B, et al . Occupationally related angiosarcoma of the liver in the United Kingdom, 1972-1994. Gut 1996; 39: 312-318. (Pubitemid 26276012)
6. Mark RJ, Poen JC, Tran LM, et al . Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996; 77: 2400-2406. (Pubitemid 26162437)
7. Cha C, Antonescu CR, Quan ML, et al . Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239: 903-909; discussion, 909-910.
8. Robinson DA, McKinstry CS, Steiner RE, et al . Magnetic resonance imaging of the solitary hepatic mass: direct correlation with pathology and computed tomography. Clin Radiol 1987; 38: 559-568.
9. Quelle DE, Zindy F, Ashmun RA, et al . Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000. (Pubitemid 26006540)
10. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723. (Pubitemid 28155311)
11. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 1999; 96: 6937-6941. (Pubitemid 29274988)
12. Lin AW, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci USA 2001; 98: 5025-5030. (Pubitemid 32397076)
13. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6: 663-673. (Pubitemid 44285999)
14. McKeller RN, Fowler JL, Cunningham JJ, et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA 2002; 99: 3848-3853. (Pubitemid 34252194)
15. Silva RL, Thornton JD, Martin AC, et al . Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J 2005; 24: 2803-2814. (Pubitemid 41170029)
16. Thornton JD, Silva RL, Martin AC, et al. The Arf tumor suppressor regulates platelet-derived growth factor receptor-β signaling: a new view through the eyes of Arf-/- mice. Cell Cycle 2005; 4: 1316-1319. (Pubitemid 41437110)
17. Gromley A, Churchman ML, Zindy F, et al . Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proc Natl Acad Sci USA 2009; 106: 6285-6290.
18. Martin AC, Thornton JD, Liu J, et al . Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest Ophthalmol Vis Sci 2004; 45: 3387-3396. (Pubitemid 39298553)
19. Zimmerli B, Schlatter J. Ethyl carbamate: analytical methodology, occurrence, formation, biological activity and risk assessment. Mutat Res 1991; 259: 325-350.
20. Forkert PG. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 2010; 42: 355-378.
21. Barbin A. Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. Mutat Res 2000; 462: 55-69. (Pubitemid 30190214)
22. Creech JL Jr, Johnson MN. Angiosarcoma of liver in the manufacture of polyvinyl chloride. J Occup Med 1974; 16: 150-151.
23. Tannenbaum A, Silverstone H. Urethane (ethyl carbamate) as a multipotential carcinogen. Cancer Res 1958; 18: 1225-1231.
24. Kawamoto S, Kirschbaum A, Ibanez ML, et al. Influence of urethane on the development of spontaneous leukemia and on the induction of hemagiomas in the AKR and C58 strains of mice. Cancer Res 1961; 21: 71-74.
25. Inai K, Arihiro K, Takeshima Y, et al . Quantitative risk assessment of carcinogenicity of urethane (ethyl carbamate) on the basis of long-term oral administration to B6C3F1 mice. Jpn J Cancer Res 1991; 82: 380-385.
26. Beland FA, Benson RW, Mellick PW, et al . Effect of ethanol on the tumorigenicity of urethane (ethyl carbamate) in B6C3F1 mice. Food Chem Toxicol 2005; 43: 1-19.
27. Cadranel JF, Legendre C, Desaint B, et al . Liver disease from surreptitious administration of urethane. J Clin Gastroenterol 1993; 17: 52-56. (Pubitemid 23193780)
28. Kamijo T, Zindy F, Roussel MF, et al . Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659. (Pubitemid 27513656)
29. Donehower LA, Harvey M, Slagle BL, et al . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
30. Thoolen B, Maronpot RR, Harada T, et al . Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 2010; 38: S 5-81.
31. Kamijo T, Bodner S, van de Kamp E, et al . Tumor spectrum in ARF-deficient mice. Cancer Res 1999; 59: 2217-2222. (Pubitemid 29217688)
32. Kemp CJ. Hepatocarcinogenesis in p53-deficient mice. Mol Carcinog 1995; 12: 132-136.
33. Zietz C, Rossle M, Haas C, et al . MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998; 153: 1425-1433. (Pubitemid 28509898)
34. Naka N, Tomita Y, Nakanishi H, et al . Mutations of p53 tumorsuppressor gene in angiosarcoma. Int J Cancer 1997; 71: 952-955. (Pubitemid 27252874)
35. Carmichael NG, Debruyne EL, Bigot-Lasserre D. The p53 heterozygous knockout mouse as a model for chemical carcinogenesis in vascular tissue. Environ Health Perspect 2000; 108: 61-65. (Pubitemid 30064096)
36. Hollstein M, Marion MJ, Lehman T, et al . p53 mutations at A: T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994; 15: 1-3. (Pubitemid 24121615)
37. Cohen SM, Storer RD, Criswell KA, et al . Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci 2009; 111: 4-18.
38. Ma W, Tessarollo L, Hong SB, et al . Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 2003; 63: 5320-5328. (Pubitemid 37139846)
39. Huang HY, Illei PB, Zhao Z, et al . Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23: 548-558. (Pubitemid 46224232)
40. Takahira T, Oda Y, Tamiya S, et al . Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. Cancer Sci 2004; 95: 651-655. (Pubitemid 39255812)
41. Oda Y, Yamamoto H, Takahira T, et al . Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 2005; 207: 410-421. (Pubitemid 43025689)
42. Niini T, Lahti L, Michelacci F, et al . Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes Cancer 2011; 50: 291-306.
43. Benassi MS, Molendini L, Gamberi G, et al . Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer 2001; 92: 3062-3067. (Pubitemid 33136202)
44. Oh JH, Kim HS, Kim HH, et al . Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop 2006; 442: 216-222. (Pubitemid 44384187)
45. Serakinci N, Guldberg P, Burns JS, et al . Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004; 23: 5095-5098. (Pubitemid 38938744)
46. Burns JS, Abdallah BM, Guldberg P, et al . Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res 2005; 65: 3126-3135. (Pubitemid 40524593)
47. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315. (Pubitemid 39551658)
48. Dragani TA, Manenti G, Colombo BM, et al . Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. Oncogene 1991; 6: 333-338. (Pubitemid 21902681)
49. Maronpot RR, Fox T, Malarkey DE, et al . Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 1995; 101: 125-156.
50. Horio Y, Chen A, Rice P, et al . Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog 1996; 17: 217-223. (Pubitemid 27050722)
51. Marion MJ, Froment O, Trepo C. Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog 1991; 4: 450-454.
52. Przygodzki RM, Finkelstein SD, Keohavong P, et al . Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras2 . Lab Invest 1997; 76: 153-159. (Pubitemid 27058206)
53. Kelly-Spratt KS, Gurley KE, Yasui Y, et al . p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol 2004; 2: E242.
54. Christophorou MA, Ringshausen I, Finch AJ, et al . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214-217. (Pubitemid 44387609)
55. Efeyan A, Garcia-Cao I, Herranz D, et al . Tumour biology: policing of oncogene activity by p53. Nature 2006; 443: 159. (Pubitemid 44387596)
56. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2: 331-341. (Pubitemid 37328946)
57. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf : progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83. (Pubitemid 36143931)
58. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all? Nat Rev Mol Cell Biol 2006; 7: 667-677. (Pubitemid 44268212)
59. Berger JH, Bardeesy N. Modeling INK4/ARF tumor suppression in the mouse. Curr Mol Med 2007; 7: 63-75. (Pubitemid 46322279)
60. Saporita AJ, Maggi LB, Jr., Apicelli AJ, et al . Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem 2007; 14: 1815-1827. (Pubitemid 47163401)
61. Maher EA, Furnari FB, Bachoo RM, et al . Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333. (Pubitemid 32524640)
62. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22: 3092-3098.
63. Conway C, Beswick S, Elliott F, et al . Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 2010; 49: 425-438.
64. Kosemehmetoglu K, Gedikoglu G, Ruacan S. Morphological and immunohistochemical features of malignant vascular tumors with special emphasis on GLUT1 and FKBP12 expressions. Turk Patoloji Derg 2011; 27: 57-67.
65. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112. (Pubitemid 41039110)
66. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.